These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34212566)

  • 1. Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report.
    Primorac D; Stojanović Stipić S; Strbad M; Girandon L; Barlič A; Frankić M; Ivić I; Marasović Krstulović D; Jukić I; Halassy B; Hećimović A; Matišić V; Molnar V
    Croat Med J; 2021 Jun; 62(3):288-296. PubMed ID: 34212566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19-Induced ARDS Patients: A Case Report.
    Kim K; Bae KS; Kim HS; Lee WY
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556900
    [No Abstract]   [Full Text] [Related]  

  • 6. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
    Can A; Coskun H
    Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
    Qin H; Zhao A
    Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 10. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
    Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
    Front Immunol; 2022; 13():932360. PubMed ID: 35860245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
    Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
    Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
    Barros I; Silva A; de Almeida LP; Miranda CO
    Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualized Analyses of Investigations Upon Mesenchymal Stem/stromal Cell-based Cytotherapy and Underlying Mechanisms for COVID-19 Associated ARDS.
    Aitong W; Leisheng Z; Hao Y
    Curr Stem Cell Res Ther; 2022; 17(1):2-12. PubMed ID: 34254927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
    Rogers CJ; Harman RJ; Bunnell BA; Schreiber MA; Xiang C; Wang FS; Santidrian AF; Minev BR
    J Transl Med; 2020 May; 18(1):203. PubMed ID: 32423449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
    Ringdén O; Moll G; Gustafsson B; Sadeghi B
    Front Immunol; 2022; 13():839844. PubMed ID: 35371003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.
    Sengupta V; Sengupta S; Lazo A; Woods P; Nolan A; Bremer N
    Stem Cells Dev; 2020 Jun; 29(12):747-754. PubMed ID: 32380908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.
    Grumet M; Sherman J; Dorf BS
    Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report.
    Zengin R; Beyaz O; Koc ES; Akinci IO; Kocagoz S; Sagcan G; Ovali E; Cuhadaroglu C
    Stem Cell Investig; 2020; 7():17. PubMed ID: 33110915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stem cells and their derived exosomes to combat Covid-19.
    Yousefi Dehbidi M; Goodarzi N; Azhdari MH; Doroudian M
    Rev Med Virol; 2022 Mar; 32(2):e2281. PubMed ID: 34363275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.